Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia

High baseline clearance of immune checkpoint inhibitors (ICIs), independent of dose or systemic exposure, is associated with cachexia and poor outcomes in cancer patients. Mechanisms linking ICI clearance, cachexia and ICI therapy failure are unknown. Here, we evaluate in four murine models and acro...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Trang T. Vu, Kyeongmin Kim, Millennium Manna, Justin Thomas, Bryan C. Remaily, Emma J. Montgomery, Travis Costa, Lauren Granchie, Zhiliang Xie, Yizhen Guo, Min Chen, Alyssa Marie M. Castillo, Samuel K. Kulp, Xiaokui Mo, Sridhar Nimmagadda, Paul Gregorevic, Dwight H. Owen, Latha P. Ganesan, Thomas A. Mace, Christopher C. Coss, Mitch A. Phelps
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2024-01-01
Saila:	Pharmacological Research
Gaiak:	Cachexia Immune Checkpoint Inhibitor Clearance FcRn LLC MC38
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S1043661823004048
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!